Anxa2 drives the function of immune suppressive neutrophils in lung cancer

摘要 尽管免疫检查点抑制物(ICI)治疗在临床上取得了巨大的成功，但只有~20%的非 小细胞肺癌(NSCLC)患者对抗PD1/PDL1治疗有反应。在努力改善这一数字时， 该领域已经启动了800多项临床试验(涉及所有癌症类型)，测试联合使用的新疗法 有免疫检查站封锁。不幸的是，这样的试验在很大程度上是基于理论 考虑因素，而不是从实际的人类癌症样本中获得的数据。值得注意的是，这些试验中很少有 定位于髓系细胞，但无一定位于中性粒细胞。我们小组最近进行了一次 综合免疫表型项目以确定人类非小细胞肺癌潜在的免疫抑制因素。 我们发现，在51种免疫细胞类型中，中性粒细胞是最常见的免疫细胞类型， 评估的亚型。更重要的是，中性粒细胞系细胞的存在与CD8+呈负相关 TME内的淋巴细胞含量。在这里，我们将展示肿瘤来源的Annexin-A2使中性粒细胞极化为 免疫抑制表型，并确定其作用机制。更重要的是，这 项目将为研究生提供必要的培训场地，以获得关键的技能和关键技能 为了在成为独立科学家的职业生涯中取得进步，他对数据进行了审查。

ABSTRACT Although immune checkpoint inhibitor (ICI) therapy has been a tremendous clinical success, just ~20% of non- small cell lung cancer (NSCLC) patients respond to anti-PD1/PDL1 therapy. In efforts to improve upon this figure, the field has launched over 800 clinical trials (across all cancer types) testing novel therapeutics in conjunction with immune checkpoint blockade. Unfortunately, such trials have been based largely on theoretical considerations and not by data obtained from actual human cancer specimens. Notably, very few of these trials address myeloid lineage cells and none of them address the neutrophil lineage. Our group recently undertook a comprehensive immune phenotyping project to identify potential immune suppressive factors in human NSCLC. We found that neutrophils were the most prevalent immune cell type out of the 51 immune cell types and subtypes assessed. More importantly, the presence of neutrophil lineage cells inversely correlated with CD8+ lymphocyte content within the TME. Here, we will show tumor-derived Annexin-A2 polarizes neutrophils to an immune suppressive phenotype and determine the mechanisms by which it does so. More importantly, this project will provide the necessary training ground for the graduate student to obtain the skills and critical examination of data to progress in his career towards an independent scientist.